Key eligibility criteria included unresectable stage IIIB, IIIC, or IV non-squamous NSCLC, treatment naivety, ECOG PS 0-2, and RET locally tested using NGS (58% of the cases) or RT-PCR (42%), but asymptomatic or stable CNS metastases were allowed. This evidence concerns the gene RET and non-small cell lung carcinoma.